MicroRNA profiles help assess cancer risk in Lynch syndrome carriers

In his doctoral dissertation completed at the University of Jyväskylä, Finland, Tero Sievänen demonstrates that the cancer risk of Lynch syndrome carriers can be assessed based on circulating microRNA profiles. This helps in developing current screening methods and targeting screenings for high-risk individuals. Additionally, the study corroborates previous findings by demonstrating that a healthy lifestyle can mitigate cancer risk in Lynch syndrome carriers. Lifestyle factors, such as weight gain, and their association with cancer development were found to be particularly pronounced in men

Lynch syndrome is a hereditary cancer syndrome that predisposes its carriers to various cancers, especially colorectal cancers. Due to the hereditary cancer risk, Lynch syndrome carriers undergo cancer screenings throughout their lives. However, current research indicates the need to improve the current screening methods to better account for individual cancer risk and more effectively target high-risk carriers.

It has been shown that circulating microRNA profiles can be used in predicting non-hereditary colorectal cancer development. MicroRNAs are small molecules that regulate gene expression in their target tissues, in response to factors such as diseases and physical activity. Circulating microRNAs are also an important part of intercellular communication, which is why their levels can reflect changes occurring in tissues.

The aim of this study was to assess whether circulating microRNA profiles can be used to predict cancer development in Lynch syndrome carriers during a four-year follow-up period.

Additionally, the study investigated the potential association between circulating microRNA profiles and lifestyle factors related to cancer risk, such as high body mass index and low physical activity."

Tero Sievänen

The study observed that that the circulating microRNA profiles of cancer-free Lynch syndrome carriers differed significantly from healthy controls but were similar to those of patients with non-hereditary colorectal cancer. Additionally, circulating microRNAs predicted colorectal cancer development during the prospective surveillance period.

"These results align with previous research findings in that changes in microRNA profiles predict the development of colorectal cancer," Sievänen notes.

"In Lynch syndrome, colorectal cancer can develop much more rapidly than in those without a hereditary predisposition to the disease. When cancer is detected early, it is easier to treat."

Physical activity and weight maintenance might reduce Lynch syndrome cancer risk

Previous studies suggest that Lynch syndrome cancer risk can be reduced through a healthy lifestyle. Thus, the thesis also examined how changes in adulthood body weight and physical activity impact overall cancer risk and colorectal cancer risk. It was observed that weight gain was associated with a higher cancer risk in adulthood only in men but not in women. Additionally, it was found that men who participated in guided leisure-time physical activity were less likely to develop cancer.

"Lifestyle factors and their association with cancer development differ between men and women," Sievänen explains.

"This may be due to physiological differences, such as variations and changes in body composition over the life course. Adhering to healthy lifestyle is important also for Lynch syndrome carriers."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients